SkinBioTherapeutics PLC (SBTX) — Financial Flexibility Index
SkinBioTherapeutics PLC (SBTX) has a Financial Flexibility Index of -0.18x as of June 2025. Free cash flow of GBX-491.17K (operating CF GBX-494.84K minus capex GBX3.66K) represents 0% of total liabilities (GBX2.71 Million). Check asset allocation strategy of SkinBioTherapeutics PLC to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SkinBioTherapeutics PLC Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for SkinBioTherapeutics PLC across 10 annual periods. See SkinBioTherapeutics PLC working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for SkinBioTherapeutics PLC (2016–2025)
Year-by-year free cash flow to debt coverage for SkinBioTherapeutics PLC. For the full company profile including market capitalisation, see SBTX company net worth.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.29 Million | GBX-1.30 Million | GBX2.71 Million | ▲ +57.6% |
| 2024 | -1.13x | GBX-2.53 Million | GBX-2.73 Million | GBX2.25 Million | ▲ +72.8% |
| 2023 | -4.14x | GBX-2.48 Million | GBX-2.65 Million | GBX599.34K | ▲ +2.1% |
| 2022 | -4.23x | GBX-2.58 Million | GBX-2.67 Million | GBX609.61K | ▼ -52.2% |
| 2021 | -2.78x | GBX-1.44 Million | GBX-1.56 Million | GBX519.67K | ▼ -3.4% |
| 2020 | -2.69x | GBX-818.47K | GBX-892.14K | GBX304.83K | ▲ +77.0% |
| 2019 | -11.69x | GBX-1.42 Million | GBX-1.43 Million | GBX121.33K | ▼ -310.9% |
| 2018 | -2.85x | GBX-595.49K | GBX-667.75K | GBX209.29K | ▲ +36.4% |
| 2017 | -4.47x | GBX-530.50K | GBX-609.70K | GBX118.66K | ▼ -211.4% |
| 2016 | 4.01x | GBX135.05K | GBX-1.17K | GBX33.64K | — |